Literature DB >> 16275157

The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer.

Pornchai O-Charoenrat1, Patchariya Khantapura.   

Abstract

Matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) play an important role in several stages of cancer initiation and development. Single nucleotide polymorphisms identified in the promoters of MMP2 (-1306C-->T) and TIMP2 (-418G-->C) abolish the Sp1-binding site and thus may down-regulate expression of the genes. We examined the contribution of these polymorphisms to susceptibility and aggressiveness of head and neck squamous cell carcinoma (HNSCC). MMP2 genotypes were determined by PCR-based allele-specific refractory mutation analysis and TIMP2 genotypes identified by PCR-RFLP in a panel of HNSCC cell lines and in 239 head and neck cancer patients and 250 frequency matched controls in an ethnic Thai population. We found that subjects with the MMP2 CC genotype was associated with significantly increased risk [adjusted odds ratio (OR), 1.97; 95% confidence interval (95% CI), 1.23-3.15] for developing HNSCC compared with those with the variant genotype (-1306CT or TT). For TIMP2, a moderately increased risk of the cancer (OR, 1.43; 95% CI, 0.98-2.08) was also associated with the variant allele (-418GC or CC), compared with the GG common allele. Furthermore, the polymorphisms in both genes showed some additive effect and the highest risk for head and neck cancer was observed in those with MMP2 CC genotype and TIMP2 variant GC or CC genotype (OR, 2.34; 95% CI, 1.31-4.18). A correlation between promoter polymorphisms and the levels of mRNA expression in cell lines and cancer tissues was found. Finally, the MMP2 CC genotype was correlated with adverse clinicopathological variables. These findings suggest that the genetic polymorphisms in the promoters of MMP2 and TIMP2 may be associated with the development and aggressiveness of HNSCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275157     DOI: 10.1016/j.oraloncology.2005.07.008

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  15 in total

1.  No Association of Matrix Metalloproteinase [MMP]-2 (-735C > T) and Tissue Inhibitor of Metalloproteinase [TIMP]-2 (-418G > C) Gene Polymorphisms with Cervical Cancer Susceptibility.

Authors:  Priyanka Srivastava; Saumya Pandey; Balraj Mittal; Rama D Mittal
Journal:  Indian J Clin Biochem       Date:  2012-07-03

2.  Pathological and prognostic significance of matrix metalloproteinase-2 expression in ovarian cancer: a meta-analysis.

Authors:  Chao Liu
Journal:  Clin Exp Med       Date:  2015-06-30       Impact factor: 3.984

Review 3.  Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.

Authors:  Ajay Kumar Chaudhary; Mamta Singh; Alok C Bharti; Kamlesh Asotra; Shanthy Sundaram; Ravi Mehrotra
Journal:  J Biomed Sci       Date:  2010-02-15       Impact factor: 8.410

4.  Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer.

Authors:  Fan-Chang Zeng; Song Cen; Zheng-Yan Tang; Xin-Li Kang
Journal:  Oncol Lett       Date:  2016-02-04       Impact factor: 2.967

5.  Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival.

Authors:  Neeraja B Peterson; Alicia Beeghly-Fadiel; Yu-Tang Gao; Jirong Long; Qiuyin Cai; Xiao-ou Shu; Wei Zheng
Journal:  Int J Cancer       Date:  2009-08-15       Impact factor: 7.396

6.  Polymorphisms in the promoters of MMP-2 and TIMP-2 genes in patients with acne vulgaris.

Authors:  Kursat Oguz Yaykasli; Hakan Turan; Ertugrul Kaya; Omer Faruk Hatipoglu
Journal:  Int J Clin Exp Med       Date:  2013-10-25

7.  Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis.

Authors:  Dan Liu; Hong Guo; Yafei Li; Xueqing Xu; Kang Yang; Yun Bai
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

8.  Investigation of the role of MMP3 -1171insA polymorphism in cutaneous malignant melanoma - a preliminary study.

Authors:  Tatyana Vlaykova; Mateusz Kurzawski; Tanya Tacheva; Dimo Dimov; Maya Gulubova; Yovcho Yovchev; Stoyan Chakarov; Marek Drozdzik
Journal:  Biotechnol Biotechnol Equip       Date:  2014-11-13       Impact factor: 1.632

9.  Frequency of the common promoter polymorphism MMP2 -1306 C>T in a population from central Bulgaria.

Authors:  Tanya Tacheva; Pavlina Chelenkova; Dimo Dimov; Rumena Petkova; Stoyan Chakarov; Tatyana Vlaykova
Journal:  Biotechnol Biotechnol Equip       Date:  2015-01-28       Impact factor: 1.632

10.  Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk.

Authors:  Caiyun Zhang; Chao Li; Minhui Zhu; Qingzhou Zhang; Zhenghua Xie; Gang Niu; Xicheng Song; Lei Jin; Guojun Li; Hongliang Zheng
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.